FDA approval feels like the finish line. It’s not.

In this episode, we break down one of the most dangerous assumptions in MedTech go-to-market: that regulatory approval leads to commercial success.

It doesn’t.

We introduce the concept of buyability - the real-world ability of hospitals and healthcare systems to adopt, pay for, and implement a product under actual economic and operational conditions.

You’ll hear why:

We also unpack how hospital decisions actually happen including the role of Value Analysis Committees (VAC), budget ownership, procurement dynamics, and the hidden reasons deals quietly die.

If you're a MedTech founder, CEO, or commercial leader operating in the U.S. market, this episode will challenge how you define pipeline, traction, and growth.

Because approval gives you permission to sell.